FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4306661100> ?p ?o ?g. }

• W4306661100 endingPage "182" @default.
• W4306661100 startingPage "175" @default.
• W4306661100 abstract "Background: Colorectal cancer is the third most prevalent cancer worldwide as 1.80 million new cases of the cancer were diagnosed and 862,000 patients died in 2018. Depending on the stage, upfront surgery is the main form of treatment, followed by adjuvant chemotherapy. Moreover, many drugs are approved by the U.S. Food and Drug Administration to treat Colorectal cancer including Capecitabine. However, during cancer treatment, the measurement of patient-reported symptoms experience and quality of life can provide additional information to evaluate and compare the efficacy and toxicity profiles of the treatments. Despite the importance of patients' quality of life during treatment while they are on anti-cancer treatment, there was no published data in the literature evaluating this vital parameter concerning Iraqi patients receiving anti-cancer drugs, in general, or those on Capecitabine, in particular. Therefore, the aim of current study was to evaluate quality of life of Iraqi patients with colorectal cancer treated with Capecitabine. Methods: A cross-sectional, open-label prospective study was conducted at Al-Amal and Oncology Teaching Hospitals in Baghdad during the period from November 2021 to June 2022. A convenient sampling method was adopted to enrol patients in the current study. Quality of life assessment was performed using the European Organization for Research and Treatment of Cancer quality of life questionnaire (QLQ-C30). Microsoft Excel 2019 and the Statistical Package for the Social Sciences (SPSS, Version 25) were used for data entry and analysis. The descriptive analysis focused on frequencies and percentages. Continuous variables were presented as mean (± Standard Deviation). Categorical data were presented as proportions and the Chi-squared test was used for the difference between two proportions. The level of significance was considered at P≤0.05. Results: A total of 102 patients were enrolled in the current study. Generalized fatigue was the most common adverse event as it presented in 63.7% of participants. Also, only 6.9% of participants had abnormal renal function tests. In addition, some capecitabine-treated patients had good quality of life, others did not. Conclusion: The quality of life of capecitabine-treated colorectal cancer patients seems to be sensitive to their sociodemographic characteristics and adverse effects profile of the drug." @default.
• W4306661100 created "2022-10-18" @default.
• W4306661100 creator A5010601094 @default.
• W4306661100 date "2022-10-17" @default.
• W4306661100 modified "2023-10-14" @default.
• W4306661100 title "Quality of life in capecitabine-treated patients with colorectal cancer is affected by their sociodemographic characteristics and their experience of the drug-related adverse effects" @default.
• W4306661100 doi "https://doi.org/10.32007/jfacmedbagdad.6431970" @default.
• W4306661100 hasPublicationYear "2022" @default.
• W4306661100 type Work @default.
• W4306661100 citedByCount "0" @default.
• W4306661100 crossrefType "journal-article" @default.
• W4306661100 hasAuthorship W4306661100A5010601094 @default.
• W4306661100 hasBestOaLocation W43066611001 @default.
• W4306661100 hasConcept C121608353 @default.
• W4306661100 hasConcept C126322002 @default.
• W4306661100 hasConcept C143998085 @default.
• W4306661100 hasConcept C146357865 @default.
• W4306661100 hasConcept C151730666 @default.
• W4306661100 hasConcept C159110408 @default.
• W4306661100 hasConcept C197934379 @default.
• W4306661100 hasConcept C2777909004 @default.
• W4306661100 hasConcept C2779951463 @default.
• W4306661100 hasConcept C526805850 @default.
• W4306661100 hasConcept C71924100 @default.
• W4306661100 hasConcept C86803240 @default.
• W4306661100 hasConceptScore W4306661100C121608353 @default.
• W4306661100 hasConceptScore W4306661100C126322002 @default.
• W4306661100 hasConceptScore W4306661100C143998085 @default.
• W4306661100 hasConceptScore W4306661100C146357865 @default.
• W4306661100 hasConceptScore W4306661100C151730666 @default.
• W4306661100 hasConceptScore W4306661100C159110408 @default.
• W4306661100 hasConceptScore W4306661100C197934379 @default.
• W4306661100 hasConceptScore W4306661100C2777909004 @default.
• W4306661100 hasConceptScore W4306661100C2779951463 @default.
• W4306661100 hasConceptScore W4306661100C526805850 @default.
• W4306661100 hasConceptScore W4306661100C71924100 @default.
• W4306661100 hasConceptScore W4306661100C86803240 @default.
• W4306661100 hasIssue "3" @default.
• W4306661100 hasLocation W43066611001 @default.
• W4306661100 hasOpenAccess W4306661100 @default.
• W4306661100 hasPrimaryLocation W43066611001 @default.
• W4306661100 hasRelatedWork W1974190027 @default.
• W4306661100 hasRelatedWork W2029040122 @default.
• W4306661100 hasRelatedWork W2058385450 @default.
• W4306661100 hasRelatedWork W2060052656 @default.
• W4306661100 hasRelatedWork W2145753255 @default.
• W4306661100 hasRelatedWork W2387874833 @default.
• W4306661100 hasRelatedWork W2601851885 @default.
• W4306661100 hasRelatedWork W3004259476 @default.
• W4306661100 hasRelatedWork W349909140 @default.
• W4306661100 hasRelatedWork W2408888651 @default.
• W4306661100 hasVolume "64" @default.
• W4306661100 isParatext "false" @default.
• W4306661100 isRetracted "false" @default.
• W4306661100 workType "article" @default.